Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ce |
RCV001093201 | SCV001250061 | uncertain significance | not provided | 2022-12-01 | criteria provided, single submitter | clinical testing | SETX: PM2, PP3 |
Labcorp Genetics |
RCV001242996 | SCV001416124 | benign | Amyotrophic lateral sclerosis type 4; Spinocerebellar ataxia, autosomal recessive, with axonal neuropathy 2 | 2023-11-01 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001093201 | SCV002552744 | uncertain significance | not provided | 2022-01-20 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Mayo Clinic Laboratories, |
RCV001093201 | SCV005410860 | uncertain significance | not provided | 2024-04-15 | criteria provided, single submitter | clinical testing | PM2_moderate |
Prevention |
RCV004536143 | SCV004118264 | uncertain significance | SETX-related disorder | 2024-02-23 | no assertion criteria provided | clinical testing | The SETX c.377A>G variant is predicted to result in the amino acid substitution p.His126Arg. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.0070% of alleles in individuals of European (Non-Finnish) descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |